JP2008001722A5 - - Google Patents

Info

Publication number

JP2008001722A5

JP2008001722A5 JP2007238577A JP2007238577A JP2008001722A5 JP 2008001722 A5 JP2008001722 A5 JP 2008001722A5 JP 2007238577 A JP2007238577 A JP 2007238577A JP 2007238577 A JP2007238577 A JP 2007238577A JP 2008001722 A5 JP2008001722 A5 JP 2008001722A5

Authority

JP

Japan

Prior art keywords

therapeutic agent

composition

glutathione

agent according

extender

Prior art date

2007-09-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 30
• 239000000203 mixture Substances 0.000 claims 30
• 229940124597 therapeutic agent Drugs 0.000 claims 30
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 20
• 108010053070 Glutathione Disulfide Proteins 0.000 claims 16
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims 16
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims 15
• 239000004606 Fillers/Extenders Substances 0.000 claims 11
• 150000003839 salts Chemical class 0.000 claims 6
• 229960003180 glutathione Drugs 0.000 claims 5
• 108010024636 Glutathione Proteins 0.000 claims 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 4
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 4
• 229930010555 Inosine Natural products 0.000 claims 4
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 4
• 229960003786 inosine Drugs 0.000 claims 4
• 229960003151 mercaptamine Drugs 0.000 claims 4
• 239000000243 solution Substances 0.000 claims 4
• 201000011510 cancer Diseases 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 230000003394 haemopoietic effect Effects 0.000 claims 3
• 208000006454 hepatitis Diseases 0.000 claims 3
• 231100000283 hepatitis Toxicity 0.000 claims 3
• 208000035473 Communicable disease Diseases 0.000 claims 2
• 206010061598 Immunodeficiency Diseases 0.000 claims 2
• 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
• 206010025323 Lymphomas Diseases 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 230000037396 body weight Effects 0.000 claims 2
• 150000001875 compounds Chemical class 0.000 claims 2
• 230000001419 dependent effect Effects 0.000 claims 2
• 208000026278 immune system disease Diseases 0.000 claims 2
• 230000007813 immunodeficiency Effects 0.000 claims 2
• 208000015181 infectious disease Diseases 0.000 claims 2
• 230000001394 metastastic effect Effects 0.000 claims 2
• 206010061289 metastatic neoplasm Diseases 0.000 claims 2
• 230000001613 neoplastic effect Effects 0.000 claims 2
• 208000015122 neurodegenerative disease Diseases 0.000 claims 2
• 210000000056 organ Anatomy 0.000 claims 2
• 238000007911 parenteral administration Methods 0.000 claims 2
• 230000035755 proliferation Effects 0.000 claims 2
• 230000005855 radiation Effects 0.000 claims 2
• 239000000126 substance Substances 0.000 claims 2
• 208000019553 vascular disease Diseases 0.000 claims 2
• 102100031126 6-phosphogluconolactonase Human genes 0.000 claims 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 claims 1
• 208000030507 AIDS Diseases 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 208000027932 Collagen disease Diseases 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 claims 1
• 108090000695 Cytokines Proteins 0.000 claims 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
• 108090000790 Enzymes Proteins 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 206010018364 Glomerulonephritis Diseases 0.000 claims 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims 1
• 108010063907 Glutathione Reductase Proteins 0.000 claims 1
• 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
• 206010062016 Immunosuppression Diseases 0.000 claims 1
• 201000009906 Meningitis Diseases 0.000 claims 1
• 201000004681 Psoriasis Diseases 0.000 claims 1
• 206010040047 Sepsis Diseases 0.000 claims 1
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims 1
• 208000026935 allergic disease Diseases 0.000 claims 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 230000002950 deficient Effects 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 230000001506 immunosuppresive effect Effects 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 229940102223 injectable solution Drugs 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• 206010025135 lupus erythematosus Diseases 0.000 claims 1
• 230000036210 malignancy Effects 0.000 claims 1
• 230000003211 malignant effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 206010034674 peritonitis Diseases 0.000 claims 1
• 230000004936 stimulating effect Effects 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 201000008827 tuberculosis Diseases 0.000 claims 1